Currently, there are 36.26M common shares owned by the public and among those 27.85M shares have been available to trade.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 2 of these insider trades were purchases, accounting for 306,242 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The company’s stock has a 5-day price change of -2.14% and -2.14% over the past three months. IKNA shares are trading -30.46% year to date (YTD), with the 12-month market performance down to -67.38% lower. It has a 12-month low price of $1.02 and touched a high of $7.64 over the same period. IKNA has an average intraday trading volume of 237.13K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -0.89%, -19.62%, and -66.33% respectively.
Institutional ownership of Ikena Oncology Inc (NASDAQ: IKNA) shares accounts for 42.81% of the company’s 36.26M shares outstanding.
It has a market capitalization of $66.12M and a beta (3y monthly) value of 0.32. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.83% over the week and 8.75% over the month.
Analysts forecast that Ikena Oncology Inc (IKNA) will achieve an EPS of $Ikena Oncology, Inc. for the current quarter, $1.37 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $iShares Genomics Immunology and while analysts give the company a high EPS estimate of $INTELAKARE MARKETING INC. Comparatively, EPS for the current quarter was $IKAN a year ago. Earnings per share for the fiscal year are expected to increase by 14.56%, and -0.57% over the next financial year.
Looking at the support for the IKNA, a number of firms have released research notes about the stock. Wedbush stated their Outperform rating for the stock in a research note on September 22, 2023, with the firm’s price target at $11.
